Related Experiment Video
Updated: Aug 12, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
Involvement of Bcl-2 cleavage in the acceleration of VP-16-induced U937 cell apoptosis
Abstract:
Apoptosis is cellular suicide functionally opposite of mitosis. It plays an important role in tissue growth control and removal of damaged and premalignant cells. The decrease in death suppressor Bcl-2 protein level was implicated in the many types of apoptotic cell death. Because Bcl-2 protein was recently found to be cleaved during apoptosis induced by Fas ligation, IL-3 withdrawal, and alphavirus infection, we assessed whether Bcl-2 protein was also cleaved during the anticancer drug (VP-16)-induced apoptotic cell death in U937 cells. We found that Bcl-2 protein was cleaved in vivo and in vitro after the treatment of VP-16. We also found that caspase-3/CPP32, which was activated after VP-16 treatment, was responsible for the direct cleavage of Bcl-2 protein. The overexpression of the cleaved Bcl-2 fragment increased the sensitivity to VP-16 and promoted apoptotic cell death. Therefore, caspase-3/CPP32 accelerates VP-16-induced U937 cell apoptosis by cleaving death suppressor Bcl-2 protein to produce a death promoter Bcl-2 fragment.
Insights
Anticancer drug VP-16 induces apoptosis by cleaving the Bcl-2 protein in U937 cells. This cleavage, mediated by caspase-3/CPP32, promotes cell death, enhancing VP-16
Area of Science:
- Cellular Biology
- Molecular Biology
- Biochemistry
Background:
- Apoptosis, or programmed cell death, is crucial for tissue homeostasis and eliminating damaged cells.
- The Bcl-2 protein typically suppresses apoptosis, but its cleavage is linked to various apoptotic pathways.
- Previous studies indicated Bcl-2 cleavage during apoptosis induced by Fas ligation, IL-3 withdrawal, and viral infections.
Purpose of the Study:
- To investigate whether Bcl-2 protein is cleaved during anticancer drug VP-16-induced apoptosis in U937 cells.
- To identify the specific protease responsible for Bcl-2 cleavage in this context.
- To determine the functional consequence of Bcl-2 cleavage on VP-16-induced apoptosis.
Main Methods:
- Treatment of U937 cells with the anticancer drug VP-16.
- Analysis of Bcl-2 protein cleavage in vivo and in vitro.
- Assessment of caspase-3/CPP32 activation following VP-16 treatment.
- Overexpression studies of cleaved Bcl-2 fragments.
Main Results:
- VP-16 treatment led to the cleavage of Bcl-2 protein in U937 cells, both in vivo and in vitro.
- Caspase-3/CPP32 was activated by VP-16 and directly cleaved the Bcl-2 protein.
- Overexpression of the cleaved Bcl-2 fragment enhanced U937 cell sensitivity to VP-16 and promoted apoptosis.
Conclusions:
- Caspase-3/CPP32 accelerates VP-16-induced apoptosis in U937 cells.
- This acceleration occurs through the direct cleavage of the death suppressor Bcl-2 protein.
- Cleavage generates a Bcl-2 fragment that promotes cell death, thus contributing to the drug's efficacy.
Related Concept Videos
Anaphase Promoting Complex
Apoptosis
Caspases
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
Cellular Injury V: Apoptosis and Autophagy

